Posts tagged "TRT"

Testosterone Cypionate

The most prescribed testosterone ester in the US, with an 8-day half-life that makes it the backbone of modern TRT. What the clinical data actually says about how to use it.

Evidence-graded profile of testosterone cypionate: pharmacokinetics, subcutaneous vs intramuscular data, the TRAVERSE trial's cardiovascular findings, age-stratified risk, and where peptides fit alongside.

testosterone-cypionatetrtdepo-testosteroneharm-reductioncypionate

TestosteroneTRT+

Testosterone Enanthate

The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.

Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.

testosterone-enanthate

TestosteroneTRT+

Testosterone Propionate

The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.

Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.

testosterone-propionate

TestosteroneTRT+

Testosterone Undecanoate

Two routes, one molecule: how undecanoate rewrote the oral testosterone playbook and what the TRAVERSE trial actually proved about heart safety.

Testosterone undecanoate is the only ester available as both a long-acting injectable (Aveed, Nebido) and a twice-daily oral (Jatenzo, Kyzatrex). Its lymphatic absorption bypasses the liver entirely, solving the hepatotoxicity problem that killed earlier oral steroids. The TRAVERSE trial confirmed cardiovascular non-inferiority, but flagged atrial fibrillation and kidney injury signals that demand ongoing monitoring.

testosterone

ResearchArticle

The Age Equation: When TRT Risk Changes and What the Alternatives Look Like

The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.

After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.

TRT

TRT

TRT

Protocols

Testosterone Cypionate

Testosterone Enanthate

Testosterone Propionate

Testosterone Undecanoate

The Age Equation: When TRT Risk Changes and What the Alternatives Look Like

Protocols

Testosterone Cypionate

Testosterone Enanthate

Testosterone Propionate

Testosterone Undecanoate

The Age Equation: When TRT Risk Changes and What the Alternatives Look Like